Tempus AI (NASDAQ:TEM) Trading 11.3% Higher – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM) shares traded up 11.3% during mid-day trading on Friday . The company traded as high as $46.07 and last traded at $46.94. 4,486,208 shares were traded during trading, a decline of 8% from the average session volume of 4,902,042 shares. The stock had previously closed at $42.17.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Needham & Company LLC lifted their price objective on Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Loop Capital reduced their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Piper Sandler reduced their price objective on Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. JPMorgan Chase & Co. cut Tempus AI from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $50.00 to $55.00 in a research report on Tuesday, February 25th. Finally, Wolfe Research cut Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $61.18.

Tempus AI Stock Up 12.1 %

The business has a 50-day simple moving average of $55.15 and a two-hundred day simple moving average of $51.92. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Transactions at Tempus AI

In other news, major shareholder Bradley A. Keywell sold 170,720 shares of Tempus AI stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $35.45, for a total value of $6,052,024.00. Following the transaction, the insider now directly owns 15,993,729 shares in the company, valued at approximately $566,977,693.05. The trade was a 1.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Eric P. Lefkofsky sold 562,345 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $50.93, for a total value of $28,640,230.85. Following the transaction, the chief executive officer now owns 9,457,283 shares in the company, valued at $481,659,423.19. This represents a 5.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,755,906 shares of company stock worth $322,788,693.

Hedge Funds Weigh In On Tempus AI

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. bought a new position in Tempus AI during the third quarter valued at about $30,000. Operose Advisors LLC bought a new position in Tempus AI during the fourth quarter valued at about $25,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI during the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC boosted its holdings in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC acquired a new stake in Tempus AI during the fourth quarter valued at approximately $49,000. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.